Truqap | European Medicines Agency (EMA)

[ad_1]

Overview

Truqap is a cancer medicine used in adults to treat breast cancer that is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body) when the cancer has come back or worsened after hormonal treatment. It is used when the cancer cells have receptors (targets) for certain hormones on their surface (ER-positive) and do not have large quantities of another receptor called HER2 (HER2-negative). The cancer cells must also have been shown to have one or more mutations (changes) in the PIK3CA, AKT1 or PTEN genes. Truqap is used in combination with fulvestrant (an anti-oestrogen medicine).

If Truqap is used in women before the menopause or around the time of menopause (pre-menopausal or peri-menopausal), it should also be given in combination with a luteinising hormone-releasing hormone (LHRH) agonist (a medicine that lowers blood levels of the hormones oestrogen and progesterone).

Truqap contains the active substance capivasertib.

Truqap can only be obtained with a prescription and treatment should be started by a doctor experienced in the use of cancer treatments.

Truqap is available as tablets to be taken twice a day, approximately 12 hours apart. The tablets are taken for four consecutive days, followed by three days with no treatment. Fulvestrant is given on days 1, 15 and 29, and once monthly thereafter.

Treatment with Truqap should continue for as long as the patient benefits from it; treatment may be stopped, or the dose reduced, if the patient has unacceptable side effects.

For more information about using Truqap, see the package leaflet or contact your doctor or pharmacist.

The active substance in Truqap, capivasertib, blocks the activity of enzymes known as serine/threonine kinase (AKT) 1, 2 and 3. These enzymes play an important role in the growth and division of cancer cells with mutations in the PIK3CA, AKT1 or PTEN genes. By blocking AKT1, AKT2 and AKT3, Truqap reduces the growth of cancer cells.

Truqap, used together with fulvestrant, was shown to slow down the growth and spread of breast cancer in one main study involving 708 adults with locally advanced or metastatic ER‑positive and HER2‑negative breast cancer whose disease came back or got worse after treatment with an aromatase inhibitor (a medicine that reduces oestrogen levels).

Patients received either Truqap or placebo (a dummy treatment) in combination with fulvestrant and the main measure of effectiveness was how long patients lived without the disease getting worse. In nearly half of the patients, the cancer cells had one or more PIK3CA, AKT1 or PTEN mutations.

The study showed that in the group of patients with PIK3CA, AKT1 or PTEN mutations, those treated with Truqap plus fulvestrant lived on average for 7.3 months without the disease getting worse, compared with 3.1 months for patients given placebo plus fulvestrant.

For the full list of side effects and restrictions with Truqap, see the package leaflet.

The most common side effects with Truqap (which may affect more than 1 in 10 people) include diarrhoea, rash, nausea (feeling sick), tiredness, vomiting, stomatitis (inflammation of the lining of the mouth), hyperglycaemia (high blood glucose levels), headache and decreased appetite.

The most common severe side effects were rash, diarrhoea, hyperglycaemia, hypokalaemia (low blood potassium levels), anaemia (low levels of red blood cells) and stomatitis.

Truqap, used together with fulvestrant, was shown to slow down the growth and spread of breast cancer in adults with locally advanced or metastatic ER-positive and HER2-negative breast cancer with one or more PIK3CA, AKT1 or PTEN mutations.

Although patients treated with Truqap had more side effects than patients on placebo, the safety of Truqap in combination with fulvestrant was considered acceptable and manageable with standard care and dose modifications.

The European Medicines Agency therefore decided that Truqap’s benefits are greater than its risks and that it can be authorised for use in the EU.

The company that markets Truqap will conduct and submit the results of additional studies to further investigate the safety and effectiveness of the medicine, including in pre-menopausal women and in patients with diabetes, as the main study did not include patients with uncontrolled or insulin-dependent diabetes.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Truqap have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Truqap are continuously monitored. Suspected side effects reported with Truqap are carefully evaluated and any necessary action taken to protect patients.

Truqap received a marketing authorisation valid throughout the EU on 17 June 2024.

English (EN)
(133.08 KB – PDF)

First published: 11/07/2024

View

English (EN)
(711.08 KB – PDF)

First published: 11/07/2024Last updated: 07/03/2025

View

Product information

English (EN)
(643.78 KB – PDF)

First published: 11/07/2024Last updated: 07/03/2025

View

Latest procedure affecting product information:
II/0001

28/02/2025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

English (EN)
(66.09 KB – PDF)

First published: 11/07/2024

View

Product details

Name of medicine: Truqap
Active substance: capivasertib
International non-proprietary name (INN) or common name: capivasertib
Therapeutic area (MeSH): Breast Neoplasms
Anatomical therapeutic chemical (ATC) code: L01EX27

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Truqap is indicated in combination with fulvestrant for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations following recurrence or progression on or after an endocrine-based regimen.

In pre- or perimenopausal women, Truqap plus fulvestrant should be combined with a luteinising hormone releasing hormone (LHRH) agonist.

For men, administration of LHRH agonist according to current clinical practice standards should be considered.

[ad_2]

Source link

Subscribe now

To access premium content

Ubisoft To Develop Blockchain Games, Enjin’s $100 Million Fund

All About Play to Earn With Crypto Games (P2E)

Blockchain Gaming Industry & 5 Crypto Games to Watch

Ethereum Still Leads The Way in Blockchain Gaming

What is Binamon? Ready For Launch On August 28

Binapet Review: Breeding BSC Play-to-Earn Game

The Galaxy of Lemuria Review – Play To Earn MMORPG

BLAST Premier 2022 – Betting Tips and Schedule

Zendodo Party Review: Where NFTs Meets DeFi on WAX

BLAST Premier 2022 – Betting Tips and Schedule

Is Overwatch League Getting Outsourced A Good Thing?

Genesis Worlds Interview With CEO Jason Cassidy

Dreamverse NFT Festival: Interview With Twobadour

Inside Axie Infinity With Jihoz – Growth Lead